Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW642444 dose-finding in COPD
NCT00606684Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2008
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of vilanterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in Trough FEV1 at Day 29. Started Feb 2008; status: completed.
02
Drugs
vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00606684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606684.